Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 44.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (27.6%)
  • Dividend yield for the last twelve months 0.7%
  • Free cash flow yield -1.7% (LTM)
  • Share price is 164.7% higher than minimum and 20.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (45.4x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $2.5 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-0.4%)762.52
year average price 839.41  


year start price 837.29 2024-06-06

max close price 960.02 2024-08-30

min close price 713.71 2025-05-23

current price 764.22 2025-06-05
Common stocks: 900 605 000

Dividend Yield:  0.7%
FCF Yield LTM: -1.7%
EV / LTM EBITDA: 45.4x
EV / EBITDA annualized: 43.6x
Last revenue growth (y/y):  +45.2%
Last growth of EBITDA (y/y):  +42.9%
Historical revenue growth:  +20.4%
Historical growth of EBITDA:  +34.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 686 729
Net Debt ($m): 35 377
EV (Enterprise Value): 722 106
EBITDA LTM ($m): 15 914
EV / LTM EBITDA: 45.4x
Price to Book: 48.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-05fool.com

Should You Invest $1,000 in Eli Lilly today?

2025-06-04fool.com

Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027

2025-06-03forbes.com

LLY Stock Too Cheap At $750?

2025-05-29marketbeat.com

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

2025-05-28wsj.com

Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track

2025-05-27proactiveinvestors.com

Eli Lilly expands neuroscience pipeline with $1B acquisition of SiteOne therapeutics

2025-05-27benzinga.com

Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives

2025-05-27fool.com

Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly

2025-05-19cnbc.com

Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly

2025-05-18fool.com

Huge News for Eli Lilly Stock Investors!
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data